VISTA blockade could restore T cell function and enhance antitumor immunity.8,10,11 Anti-VISTA antibodies have demonstrated promising results in augmenting immunotherapy and improving response to chemotherapy.8,12–14 However, its specific role in RT response, particularly regarding MDSCs and tumor-associated macrophages (TAMs), remains under investigation. Here, VSIR is linked to neoplasm.